GNAZ: A Protein Involved in Neural Circuits and Various Diseases

Target Name: GNAZ

NCBI ID: G2781

GNAZ

GNAZ: A Protein Involved in Neural Circuits and Various Diseases

GNAZ (GNAZ_HUMAN) is a protein that is expressed in various tissues of the human body, including the nervous system, endocrine system, and muscle system. It is a key regulator of the nervous system, and is involved in the development and maintenance of neural circuits. GNAZ has also been shown to play a role in various diseases, including neurodegenerative disorders, and is Therefore, GNAZ has potential as a drug target or biomarker.

GNAZ is a transmembrane protein that is expressed in the nervous system, including the brain, spinal cord, and peripheral nerves. It is a key regulator of the nervous system, and is involved in the development and maintenance of neural circuits. GNAZ plays a role in the regulation of neurotransmitter release, synaptic plasticity, and neuroinflammation.

In neurodegenerative disorders, GNAZ has been shown to be involved in the development and progression of neurodegeneration. For example, studies have shown that GNAZ levels are reduced in the brains of individuals with Alzheimer's disease, and that these changes in GNAZ levels may contribute to the development of neurodegeneration in these individuals.

In addition to its role in neurodegenerative disorders, GNAZ has also been shown to be involved in various other conditions, including neuroimaging, pain perception, and motor function. For example, GNAZ has been shown to play a role in the regulation of pain perception, and has been shown to be involved in the development of chronic pain in individuals with neuroimaging.

GNAZ has also been shown to be involved in neuroinflammation, which is a major concern in the development of various neurodegenerative disorders. GNAZ has been shown to play a role in the regulation of inflammation in the brain, and has been shown to be involved in the development of neuroinflammation in individuals with neurodegenerative disorders.

GNAZ is also a good candidate as a biomarker for certain diseases. For example, GNAZ has been shown to be involved in the development and progression of multiple sclerosis, a neuroimmune disorder that causes muscle weakness and fatigue. Studies have shown that GNAZ levels are reduced in the brains of individuals with multiple sclerosis, and that these changes in GNAZ levels may contribute to the development of neuroimmune disorders.

In conclusion, GNAZ is a protein that is expressed in various tissues of the human body, and is involved in the development and maintenance of neural circuits. GNAZ has also been shown to play a role in various diseases, including neurodegenerative disorders, neuroimaging, pain perception, and motor function, and has potential as a drug target or biomarker. Further research is needed to fully understand the role of GNAZ in these conditions, and to develop effective treatments.

Protein Name: G Protein Subunit Alpha Z

Functions: Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems

The "GNAZ Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GNAZ comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets